Ed Jun

Vicepresidente de Finanzas

Ed Jun is a thoughtful leader who empowers and inspires his teams to deliver exceptional performance in alignment with the company’s goals. He is a seasoned finance leader with a strong life sciences background who drives decision making based on the needs of the business and analytical acumen. Mr. Jun leads the Finance & Accounting teams, as well as the Technology team at Ossium.

Before joining Ossium, Mr. Jun developed and led the Finance, Planning & Analysis team at Caribou Biosciences. As Caribou transitioned into a public company, he was instrumental in shaping new financial processes such as leading the budgeting, forecasting, board financials, and other financial analyses. Mr. Jun also led the FP&A function at Audentes Therapeutics, where he worked to integrate the company’s processes and financials into Astellas Pharmaceuticals. He also led the North America retail FP&A team at Activision Blizzard and spent 10 years at Pfizer in various commercial finance and FP&A roles. In 2016, Mr. Jun was recognized by the Asian American Business Development Center as one of the top 50 Outstanding Asian Americans in business.
Mr. Jun is a Navy surface warfare veteran and served for four years on two different Destroyers. Mr. Jun received his BS in Mechanical Engineering and his MBA in Finance, both from Cornell University.

Sagar Munjal

Director Médico, Vicepresidente Senior

Dr. Sagar Munjal has more than twenty years of experience in drug development and product strategy and oversees Ossium’ clinical programs, pipeline, and strategy. His expertise spans clinical development (phase I-IV), clinical operations, medical affairs, R&D, and global product launches. Dr. Munjal has worked in eight therapeutic areas and has brought four products to market and successfully negotiated a complex failed phase 3 study with the FDA to achieve product approval. He has worked extensively with regulatory and government agencies, including the FDA, EMA, MHRA, ANVISA, and the DCGI. Dr. Munjal has drug development experience in small molecules, drug-device combination products, and biologics.

Dr. Munjal has managed global teams in the US, Europe, and India. He has worked with CROs of all sizes, investors, and scientific advisors.

Antes de incorporarse a Ossium, el Dr. Munjal trabajó en Dr. Reddy's Laboratories Inc (EE.UU.), y fue Director Médico en Promius Pharma LLC, una filial propiedad al cien por cien de Dr. Reddy's. Anteriormente, trabajó en Johnson & Johnson, Altria y en la clínica como investigador. El Dr. Munjal ha publicado más de 30 manuscritos relacionados con estudios clínicos, ha presentado más de 60 resúmenes en diversas reuniones científicas y ha recibido el premio Harold G. Wolff 2017 de la American Headache Society por sus contribuciones científicas clave en el campo de la migraña. El Dr. Munjal obtuvo su doctorado en Medicina en la Universidad de Karnataka Dharwad y su máster en Investigación Clínica y Bioestadística en la Universidad Commonwealth de Virginia.

Hans Nowak

Vicepresidente de Operaciones Técnicas

Hans Nowak II is a seasoned executive known for his leadership and expertise in manufacturing and supply chain operations, engineering, and business analytics. His strategic business experience, grounded in a robust technical foundation, has enabled him to optimize operational excellence and drive transformative growth across multiple complex, regulated industries.

At Ossium Health, Mr. Nowak leads day-to-day manufacturing, supply chain, and engineering operations, overseeing production output, product quality, and distribution. He also shapes the company’s strategic and operational vision to expand the product range, innovate for company growth, bolster manufacturing capabilities, and drive continuous competitive improvement while maintaining a safety-first and quality-always mindset.

Prior to Ossium, Mr. Nowak served as a Senior Engagement Manager at McKinsey & Company, where he led pharmaceutical and medical device companies through their most challenging operations and analytics problems. His projects ranged from heading the operational, quality, and digital transformations of manufacturing networks and sites to building product development strategies that significantly reduced development time, leading to rapid approvals of new molecular entities. Before joining McKinsey, Mr. Nowak spent over a decade in engineering and operations leadership positions in industries ranging from nuclear engineering and defense to manufacturing operations and pharma.

El Sr. Nowak es veterano de los submarinos de la Armada y graduado por la Academia Naval de los Estados Unidos, donde se licenció en Matemáticas Aplicadas y en Economía Cuantitativa. Continuó su formación en el MIT como becario de Leaders for Global Operations (LGO) y Siebel Scholar, graduándose el primero de su promoción y obteniendo su máster en Ingeniería Mecánica por la Facultad de Ingeniería del MIT y su MBA por la Sloan School of Management del MIT. El Sr. Nowak está certificado en ingeniería nuclear, investigación de operaciones y análisis empresarial, y ha compartido su experiencia impartiendo cursos en prestigiosas instituciones como IUPUI y el MIT.

El Sr. Nowak es veterano de los submarinos de la Armada y graduado por la Academia Naval de los Estados Unidos, donde se licenció en Matemáticas Aplicadas y en Economía Cuantitativa. Continuó su formación en el MIT como becario de Leaders for Global Operations (LGO) y Siebel Scholar, graduándose el primero de su promoción y obteniendo su máster en Ingeniería Mecánica por la Facultad de Ingeniería del MIT y su MBA por la Sloan School of Management del MIT. El Sr. Nowak está certificado en ingeniería nuclear, investigación de operaciones y análisis empresarial, y ha compartido su experiencia impartiendo cursos en prestigiosas instituciones como IUPUI y el MIT.

Kathleen Vasilopulos

Vicepresidente de Operaciones con Donantes

Kathleen Vasilopulos is a proven operations executive, with a background in nursing, healthcare, legal consulting, business development, and organ and tissue donation. She is focused on mission-driven, life-saving healthcare initiatives. At Ossium, Ms. Vasilopulos oversees the donor ecosystem, managing relationships with recovery partners and ensuring that our donor bank continues to expand.

Prior to joining Ossium, Ms. Vasilopulos held leadership positions in healthcare and medical legal consulting. As Vice President of Hospital Development & Family Services at Donor Network West, Ms. Vasilopulos directed teams in Northern California and Nevada, significantly improving organ authorization and donation rates. At OneLegacy, the world’s largest organ, tissue, and eye procurement organization, her leadership contributed to record-breaking years for organ donation and transplantation. Ms. Vasilopulos served as Vice President of Business Development at Recruitment Specialists Inc., where she secured key contracts and managed national projects that generated millions in sales. Her career also includes successful tenures at Progressive Nursing Staffers, where she drove substantial sales and growth. Ms. Vasilopulos started her healthcare career as a Cardiovascular ICU Nurse and Team Lead. With a BSN and an MBA from the University of Illinois, as well as certifications in procurement transplant and tissue banking, she has built a reputation for exceptional leadership across various industries, consistently driving organizational growth and operational excellence.

Chip Walker-Wilson

Consejero General y Vicepresidente Primero

Chip Walker-Wilson es el Consejero General y Vicepresidente Senior, y es responsable de supervisar las funciones legales y de gobierno corporativo de Ossium Health.

Prior to joining Ossium Health, Mr. Walker-Wilson served as legal counsel at Cytokinetics, a clinical-stage biopharmaceutical company with development programs in the areas of cardiovascular and neurological diseases. At Cytokinetics, Mr. Walker-Wilson primarily supported the Research & Development Department, including the Clinical Operations, Non-Clinical Development, Research, Biometrics and Informatics groups. Prior to Cytokinetics, Mr. Walker-Wilson served as legal counsel at Dynavax Technologies Corporation, a biotechnology company with development programs in vaccines, cancer immunotherapies, and autoimmune and inflammatory diseases. At Dynavax, Mr. Walker-Wilson provided support across the company, including the Research & Development, Technical Operations, Corporate Governance, Business Development, Information Technology, Regulatory, Quality, Human Resources, and Medical Affairs groups. Prior to Dynavax, Mr. Walker-Wilson served as legal counsel at Abbott Laboratories. Mr. Walker-Wilson supported Abbott Diabetes Care, a medical device manufacturer that develops and sells blood glucose monitoring products. At Abbott, Mr. Walker-Wilson primarily worked with the Sales, Marketing, Strategic Partnership and Alliances, Business Development, and Customer Service groups. Prior to Abbott, Mr. Walker-Wilson worked at the law firms of Orrick, Herrington & Sutcliffe and Sheppard, Mullin, Richter & Hampton, where his practice focused primarily on corporate and securities law and finance law.

Mr. Walker-Wilson received his BA in Legal Studies (with a minor in Rhetoric) from the University of California, Berkeley and his JD from the University of California, Berkeley School of Law.